Kelly CRISPR & Gene Editing Technology ETF
Kelly CRISPR & Gene Editing Technology ETF
Your view on XDNA
Overview
What the company does, where it operates, and who runs it.
About Kelly CRISPR & Gene Editing Technology ETF
- Industry
- Asset Management
- Sector
- Financial Services
- CEO
- Not available
- Headquarters
- 7887 East Belleview Avenue, Suite 1100, Englewood, CO, CA
- Industry
- Asset Management
- Sector
- Financial Services
- CEO
- Not available
- Headquarters
- 7887 East Belleview Avenue, Suite 1100, Englewood, CO, CA
The fund employs a passive investment strategy, aiming to replicate the total return performance of its benchmark index. This index is rule-based, comprising equities or their corresponding depositary receipts from companies involved in the entire spectrum of DNA Modification Technology, including its invention, advancement, production, operation, provision, distribution, ownership, maintenance, licensing, leasing, or franchising. A minimum of 80% of the fund's net assets are dedicated to enterprises focused on DNA Modification Technology. This is a non-diversified fund.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks the stock is worth vs. the current price.
FRC's fair value estimate for Kelly CRISPR & Gene Editing Technology ETF, and the rating behind it. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Kelly CRISPR & Gene Editing Technology ETF. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Kelly CRISPR & Gene Editing Technology ETF. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Kelly CRISPR & Gene Editing Technology ETF. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Kelly CRISPR & Gene Editing Technology ETF. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Kelly CRISPR & Gene Editing Technology ETF valued side by side against its closest peers. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
Which funds and firms own the stock.
Which institutions hold Kelly CRISPR & Gene Editing Technology ETF, and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by Kelly CRISPR & Gene Editing Technology ETF executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Kelly CRISPR & Gene Editing Technology ETF. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Kelly CRISPR & Gene Editing Technology ETF. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Kelly CRISPR & Gene Editing Technology ETF. Press releases and market coverage, newest first.